CAMBRIDGE, Mass., July 19,
2023 /PRNewswire/ -- Akebia Therapeutics,
Inc. (Nasdaq: AKBA), a biopharmaceutical company with the
purpose to better the lives of people impacted by kidney disease,
today announced that John Butler,
Chief Executive Officer, will participate in a fireside chat at the
H.C. Wainwright 2nd Annual Kidney Conference, which will
take place as a virtual event on Tuesday,
July 25, 2023.
During the fireside chat, Mr. Butler will discuss recent
regulatory updates regarding vadadustat, Akebia's oral
hypoxia-inducible factor prolyl hydroxylase inhibitor for the
treatment of anemia due to chronic kidney disease in adult patients
on dialysis.
A webcast of the presentation can be accessed through the
Investors section of Akebia's website at
https://ir.akebia.com for approximately 90 days following the
conference.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is
a fully integrated biopharmaceutical company with the purpose to
better the lives of people impacted by kidney disease. Akebia was
founded in 2007 and is headquartered in Cambridge, Massachusetts. For more
information, please visit our website at www.akebia.com, which does
not form a part of this release.
About Vadadustat
Vadadustat is an oral
hypoxia-inducible factor prolyl hydroxylase inhibitor designed to
mimic the physiologic effect of altitude on oxygen availability. At
higher altitudes, the body responds to lower oxygen availability
with stabilization of hypoxia-inducible factor, which can lead to
increased red blood cell production and improved oxygen delivery to
tissues. Vadadustat is not approved by the U.S. Food and Drug
Administration. Vadadustat is approved in Europe for the treatment of symptomatic anemia
due to CKD in adult patients on chronic maintenance dialysis. In
Japan, vadadustat is approved as a
treatment for anemia due to CKD in both dialysis-dependent and
non-dialysis dependent adult patients.
Akebia Therapeutics Contact
Mercedes Carrasco
Mcarrasco@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-hc-wainwright-kidney-conference-301880784.html
SOURCE Akebia Therapeutics